Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Vlasak

Orthopaedic Surgery Gainesville, FL Medical Doctor

NPI 1538197298 CMS profile 342381

1600 Sw Archer Rd, Gainesville, FL 32610

Open in the dashboard

General payments

$773,209

174 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Vlasak of Gainesville, FL is reported in the CMS Open Payments database as having received $773,209 across 174 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $82,733 14
2024 General $91,224 20
2023 General $106,284 32
2022 General $124,374 31
2021 General $99,452 25
2020 General $120,639 26
2019 General $148,504 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Vlasak
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Richard Vlasak were reported at $82,733. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Richard Vlasak Orthopaedic Surgery median Middle half National median
2019 $148,504 $644 $140–$2,844 $163
2020 $120,639 $312 $75–$1,860 $114
2021 $99,452 $520 $117–$2,495 $132
2022 $124,374 $598 $128–$2,731 $149
2023 $106,284 $461 $128–$2,264 $160
2024 $91,224 $497 $134–$2,475 $164
2025 $82,733 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ortho Development Corporation $773,015 171 payments
  2. SI-BONE, Inc. $105 1 payment
  3. Exactech, Inc. $67 1 payment
  4. IlluminOss Medical, Inc. $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $766,955 146 payments
  2. Travel and Lodging $4,704 9 payments
  3. Food and Beverage $1,550 19 payments
Products named General payments · program years 2019–2025
  1. Ovation Hip Stem $440,740 63 payments
  2. Ovation $218,191 24 payments
  3. Ovation Tribute Hip Stem $139,485 49 payments
  4. Ovation Tribute $50,748 24 payments
  5. BKS Revision $136 3 payments
  6. Balanced Knee Revision System $124 1 payment
  7. Balance Knee Revision System $85 1 payment
  8. Balanced Knee System $85 1 payment
  9. Entrada $73 1 payment
  10. NOVATION HIP $67 1 payment
  11. Other $80 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

473

Median for Orthopedic Surgery: 203

Drug cost

$8,666

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 143 $3,076
Naloxone Hcl Generic 32 $1,610
Cefepime Hcl Generic 11 $1,599
Diclofenac Sodium Generic 16 $769
Mupirocin Generic 82 $513
Gabapentin Generic 32 $386
Tramadol Hcl Generic 62 $372
Oxycodone Hcl Generic 49 $205
Meloxicam Generic 22 $88
Cephalexin Generic 24 $49

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$176,812

Of which drugs: $6,637

Medicare patients

354

Average age 74

Services billed

22,614

220 women, 134 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 34%
Diabetes 32%
Ischemic heart disease 32%
Chronic kidney disease 31%
Osteoporosis 30%
Atrial fibrillation 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 66 21,520 $2,214
Injection, methylprednisolone acetate, 40 mg J1030 Office 44 217 $911

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

174 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record